Inmune Bio (INMB) Non-Current Debt (2021 - 2024)
Historic Non-Current Debt for Inmune Bio (INMB) over the last 4 years, with Q3 2024 value amounting to $2.5 million.
- Inmune Bio's Non-Current Debt rose 521.89% to $2.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.5 million, marking a year-over-year increase of 521.89%. This contributed to the annual value of $9.7 million for FY2022, which is 3292.99% down from last year.
- Inmune Bio's Non-Current Debt amounted to $2.5 million in Q3 2024, which was up 521.89% from $5.0 million recorded in Q2 2024.
- In the past 5 years, Inmune Bio's Non-Current Debt registered a high of $14.6 million during Q2 2022, and its lowest value of $2.4 million during Q3 2023.
- In the last 4 years, Inmune Bio's Non-Current Debt had a median value of $9.7 million in 2022 and averaged $9.5 million.
- Per our database at Business Quant, Inmune Bio's Non-Current Debt plummeted by 8041.06% in 2023 and then surged by 521.89% in 2024.
- Quarter analysis of 4 years shows Inmune Bio's Non-Current Debt stood at $14.5 million in 2021, then plummeted by 32.93% to $9.7 million in 2022, then plummeted by 75.5% to $2.4 million in 2023, then increased by 5.22% to $2.5 million in 2024.
- Its Non-Current Debt stands at $2.5 million for Q3 2024, versus $5.0 million for Q2 2024 and $7.5 million for Q1 2024.